Blair William & Co. IL Sells 20,677 Shares of QuidelOrtho Co. (NASDAQ:QDEL)

Blair William & Co. IL decreased its position in QuidelOrtho Co. (NASDAQ:QDEL - Free Report) by 45.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,937 shares of the company's stock after selling 20,677 shares during the quarter. Blair William & Co. IL's holdings in QuidelOrtho were worth $1,111,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Blue Trust Inc. boosted its holdings in QuidelOrtho by 188.0% during the fourth quarter. Blue Trust Inc. now owns 1,293 shares of the company's stock worth $58,000 after purchasing an additional 844 shares during the last quarter. Spire Wealth Management bought a new position in shares of QuidelOrtho during the 4th quarter worth approximately $74,000. KBC Group NV grew its holdings in shares of QuidelOrtho by 122.9% in the fourth quarter. KBC Group NV now owns 3,437 shares of the company's stock valued at $153,000 after acquiring an additional 1,895 shares in the last quarter. LPL Financial LLC purchased a new stake in shares of QuidelOrtho during the fourth quarter valued at approximately $221,000. Finally, Captrust Financial Advisors bought a new stake in QuidelOrtho during the third quarter worth $238,000. Hedge funds and other institutional investors own 99.00% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Jefferies Financial Group started coverage on QuidelOrtho in a research note on Tuesday, December 10th. They issued a "hold" rating and a $43.00 price objective for the company. Royal Bank of Canada reduced their price target on shares of QuidelOrtho from $64.00 to $61.00 and set an "outperform" rating for the company in a research report on Thursday, February 13th. StockNews.com lowered shares of QuidelOrtho from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. Citigroup raised shares of QuidelOrtho from a "neutral" rating to a "buy" rating and increased their target price for the company from $44.00 to $50.00 in a research report on Wednesday, December 11th. Finally, UBS Group boosted their target price on QuidelOrtho from $43.00 to $45.00 and gave the company a "neutral" rating in a research note on Thursday, February 13th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $51.20.

QuidelOrtho Price Performance

NASDAQ:QDEL traded up $0.23 during trading hours on Monday, hitting $28.36. The stock had a trading volume of 2,196,764 shares, compared to its average volume of 955,928. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of -0.94 and a beta of 0.43. QuidelOrtho Co. has a one year low of $26.34 and a one year high of $49.45. The company has a 50 day simple moving average of $38.72 and a two-hundred day simple moving average of $40.82. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.22 and a quick ratio of 0.69.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.07 by ($0.44). QuidelOrtho had a negative net margin of 72.84% and a positive return on equity of 3.78%. Research analysts forecast that QuidelOrtho Co. will post 2.3 earnings per share for the current fiscal year.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.